The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8849088833678833499994e346-4024-468f-af55-edf13fd451617903e58e-b2b9-4ada-b043-97e80d729fcf8306c524-7026-46f7-a180-77568626f59dARGS_News_2016_4_7_General_Releases.pdfARGS_News_2016_3_29_General_Releases.pdfARGS_News_2016_3_29_General_Releases.pdf117467199269051232016-4-7T16:5:0-4:02016-3-29T18:12:30-4:02016-3-29T16:30:14-4:0964116962585962569General ReleasesGeneral ReleasesGeneral ReleasesCompany will present update on clinical development of immunotherapies based on Arcelis® technology platformArgos Therapeutics to Participate in 15th Annual Needham Healthcare ConferenceCORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational HighlightsArgos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights131131131201620162016No Error0

Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
Read more

CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC